Revenue YoY
+5.92%
Operating Income YoY
-5.27%
Net Income YoY
-1.70%
Net Margin Δ
-234 bps
Net income bridge for Regeneron Pharmaceuticals (REGN) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Net income: −$75.90M-1.70%
Profit bridge breakdown for Regeneron Pharmaceuticals (REGN) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Net Income | $4.50B | — |
| Revenue | $833.90M | +1098.7% |
| Cost of Revenue | −$304.80M | -401.6% |
| Operating Expenses | −$731.00M | -963.1% |
| Other Income / Expense | $374.60M | +493.5% |
| Income Tax | −$248.60M | -327.5% |
| Net Income | $4.42B | — |
- Prior Net Income$4.50B
- Revenue$833.90M
- Cost of Revenue−$304.80M
- Operating Expenses−$731.00M
- Other Income / Expense$374.60M
- Income Tax−$248.60M
- Net Income$4.42B
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want the full P&L structure?Income Statement Waterfall
Frequently asked questions
Data & methodology
Regeneron Pharmaceuticals (REGN) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement